MYGN

MYRIAD GENETICS, INC.

MYGN · CIK 899923 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$825M
20182025
Net Income−$366M
20182025
Operating CF$2M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.8B$0.8B$0.8B$0.7B$0.7B$0.1B$0.2B$0.2B
Cost of Revenue$0.2B$0.3B——————
Gross Profit$0.6B$0.6B——————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense——$0.6B$0.5B$0.5B$0.1B$0.1B$0.1B
Operating Income$-0.4B$-0.1B$-0.3B$-0.1B$-0.2B$-0.1B$-0.0B$0.0B
Net Income$-0.4B$-0.1B$-0.3B$-0.1B$-0.0B$-0.1B$-0.0B$0.0B
EPS (Basic)$-3.95$-1.41$-3.18$-1.39$-0.35$-0.74$-0.06$0.19
EPS (Diluted)$-3.95$-1.41$-3.18$-1.39$-0.35$-0.74$-0.06$0.18

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.7B$1.0B$1.1B$1.2B$1.3B$1.4B$1.6B$1.2B
Current Assets$0.3B$0.3B$0.3B$0.3B$0.5B$0.3B$0.3B$0.3B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.3B$0.2B$0.1B$0.1B
Total Liabilities$0.3B$0.3B$0.4B$0.3B$0.4B$0.5B$0.5B$0.2B
Current Liabilities$0.1B$0.2B$0.2B$0.1B$0.2B$0.1B$0.1B$0.1B
Stockholders' Equity$0.4B$0.7B$0.8B$0.9B$1.0B$0.9B$1.1B$1.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$0.0B$-0.0B$-0.1B$-0.1B$0.0B$0.1B$0.1B$0.1B
Investing Cash Flow$-0.0B$-0.0B$0.0B$-0.1B$0.3B$0.0B$-0.3B$-0.0B
Capital Expenditures————————
Financing Cash Flow$0.1B$-0.0B$0.2B$-0.0B$-0.2B$-0.0B$0.2B$-0.1B
← Companies